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Head and neck cancer
Magnetic Resonance Imaging
Radiomicsa b s t r a c t
Purpose: This study investigated whether Magnetic Resonance image biomarkers (MR-IBMs) were asso-
ciated with xerostomia 12 months after radiotherapy (Xer12m) and to test the hypothesis that the ratio of
fat-to-functional parotid tissue is related to Xer12m. Additionally, improvement of the reference Xer12m
model based on parotid gland dose and baseline xerostomia, with MR-IBMs was explored.
Methods: Parotid gland MR-IBMs of 68 head and neck cancer patients were extracted from pre-treatment
T1-weighted MR images, which were normalized to fat tissue, quantifying 21 intensity and 43 texture
image characteristics. The performance of the resulting multivariable logistic regression models after
bootstrapped forward selection was compared with that of the logistic regression reference model.
Validity was tested in a small external cohort of 25 head and neck cancer patients.
Results: High intensity MR-IBM P90 (the 90th intensity percentile) values were significantly associated
with a higher risk of Xer12m. High P90 values were related to high fat concentration in the parotid glands.
The MR-IBM P90 significantly improved model performance in predicting Xer12m (likelihood-ratio-test;
p = 0.002), with an increase in internally validated AUC from 0.78 (reference model) to 0.83 (P90). The
MR-IBM P90 model also outperformed the reference model (AUC = 0.65) on the external validation cohort
(AUC = 0.83).
Conclusion: Pre-treatment MR-IBMs were associated to radiation-induced xerostomia, which supported
the hypothesis that the amount of predisposed fat within the parotid glands is associated with Xer12m.
In addition, xerostomia prediction was improved with MR-IBMs compared to the reference model.
 2018 The Authors. Published by Elsevier B.V. Radiotherapy and Oncology 128 (2018) 459–466 This is an
open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).Xerostomia is one of the most frequently reported side-effects
following radiotherapy for head and neck cancer, and has a major
impact on quality of life [1,2]. Normal Tissue Complication Proba-
bility (NTCP) models have been developed to predict radiation-
induced xerostomia and have demonstrated a clear relationship
with parotid gland dose and baseline patient-rated xerostomia
[3,4]. Nevertheless, substantial unexplained variance in predicting
xerostomia remains. Better understanding of the aetiology of
radiation-induced xerostomia is necessary to advance towards
more individualised treatments and better sparing of normal
tissues by further dose optimization, by means of new radiationtechniques, such as proton therapy [5,6] and Magnetic Resonance
Imaging (MRI) guided radiation [7].
Tumour-based image biomarkers (IBMs), which are shape,
intensity and texture characteristics extracted from images, can
contribute to the prediction of overall, disease-free and
progression-free survival [8–13]. However, the role of these IBMs
in normal tissues to predict radiation-induced toxicities is less
explored, while these are imperative in supporting treatment deci-
sions [5].
Our previous study based on IBMs from pre-treatment CT
images, demonstrated that high heterogeneous parotid gland
tissue, was associated with a higher probability of developing late
xerostomia [14]. Qualitative evaluation of the parotid glands
suggested that the predictive CT-IBM indicated the ratio between
fatty and functional parotid parenchyma tissue. In a subsequent
study, we showed that patients with low metabolic parotid glands,
460 MR-IBMs improve xerostomia predictionquantified in pre-treatment 18FDG-PET IBMs, were more likely to
develop late xerostomia. These associations also suggested that
the non-functional (which can be fatty tissue) to functional tissue
ratio is an important pre-treatment characteristic to improve pre-
diction of xerostomia [15].
MRI is superior in imaging soft tissue contrast and thereforemore
accurate in differentiating fat from the parenchymal gland tissue
compared to CT and 18FDG-PET [16]. Hence, investigating the pre-
treatment MR-IBMs of the parotid glands could, therefore, poten-
tially provide better information for predicting late xerostomia.
The purpose of this study was to test whether MR-IBMs
extracted from T1-weighted MRI scans were associated with the
development of xerostomia 12 months after radiotherapy (Xer12m)
and to investigate whether MR-IBMs can improve the xerostomia
prediction model based on parotid gland dose and baseline xeros-
tomia only. The predictive MR-IBMs were evaluated to test the
hypothesis that the fat-to-functional parenchymal parotid tissue
ratio is related to Xer12m. The findings were externally validated
in an independent cohort.Materials and methods
Patient demographics and treatment
The training and test cohort included head and neck cancer
patients that were treated with definitive radiotherapy with or
without concurrent chemotherapy or cetuximab between Septem-
ber 2012 and December 2014 at the University Medical Center
Groningen (UMCG), and between October 2010 and March 2016
at Memorial Sloan Kettering Cancer Center (MSKCC), respectively.
All patients were treated with Intensity-Modulated Radiation
Therapy (IMRT) or Volumetric Arc Therapy (VMAT) using a simul-
taneous integrated boost (SIB) technique. The parotid glands were
spared as much as possible. Patients received a total therapeutic
dose of 70 Gy over 6–7 weeks. Most patients received bilateral
neck radiation with a prophylactic dose of 54.25 Gy. Details about
the radiotherapy regimens used are described in detail in previous
studies [14,17].
Patients were excluded if they had salivary gland tumours or
underwent surgery or radiotherapy in the head and neck area prior
to or within one year after treatment. Moreover, patients without
late follow-up data were excluded. Furthermore, MRI scan quality
was visually evaluated, and if scans had considerable noise, limit-
ing both visualisation of the parotid glands and reliable estimation
of the local image intensity, patients were excluded. The final num-
ber of patients was 68 and 25 in the UMCG and MSKCC cohorts,
respectively.Fig. 1. MR-IBM extraction process. (I) MR scans were standardised with the average M
parotid glands were extracted. (III) Intensity MR-IBMs were directly extracted. (IV) The
reflection grey level transitions or repetitions.Endpoints
The primary endpoint was patient-rated moderate-to-severe
late xerostomia (Xer12m). In the UMCG cohort, this corresponds
to the 2 highest scores of the 4-point Likert scale of the EORTC
QLQ-H&N35 questionnaire and was consistently scored 12 months
after treatment, which is part of a Standard Follow-up Program
(SFP) for Head and Neck Cancer Patients (NCT02435576), as
described in previous studies [4,18].
In the MSKCC cohort, xerostomia was scored with multiple
questions with a 0–10 scale [19,20] (see Supplemental Materials 1).
Xerostomia scores were collected between 6 and 17 months
after treatment (mean ± SD: 11.0 ± 2.5 months). Moderate-to-
severe xerostomia was considered if any of the questions was
scored 6 or higher.
MRI acquisition and standardisation
In the UMCG, MR images were acquired in treatment
position on a single scanner (MAGNETOM Aera 1.5 T scanner,
Siemens Medical Systems, Knoxville, TN, USA) approximately
2 weeks before the start of radiotherapy (Spine 32, flexible 4
and 18 channel coils) for delineation purposes. T1-weighted
Turbo Spin Echo (TSE) images (TE: 22 ms; TR: 457–606 ms)
were acquired for all patients with a resolution of 0.36  0.36 
4.00 mm without the use of intravenous contrast agents or
fat-suppression.
In MSKCC, pre-treatment MR-images were acquired on MRI
scanners of different manufacturers (GE, Phillips, Siemens) and
scanners with field strength of 1.5 T (13 patients) and 3 T
(12 patients). The resolution of the non-contrast enhanced
T1-weighted TSE images (TE: 8–20 ms; TR: 400–697 ms) ranged
from 0.35x0.35 to 1.01 x1.01 mm in-plane and the slice thickness
from 3.0 to 5.0 mm.
The MRI intensity values of similar tissue types vary between
scans. Therefore, only relative intensities within one scan can be
compared. To make a comparison of the relative intensities
between patients possible, scans had to be standardised. In this
study, fat T1 characteristics were assumed consistent between
patients, and should, consequently, have similar MR-intensity val-
ues. Subcutaneous fat was delineated in both the right and left
cheek area in a minimum of 4 slices at the level of the parotid
glands of all patients (Fig. 1I). The fat area was delineated laterally
of the parotid gland, the masseter muscle and lip muscles, where
the area is delineated as large as possible while excluding non-
fat related structures. Subsequently, the MR images were multi-
plied by a fixed value, which was arbitrarily chosen to 350, and
divided by the average subcutaneous fat intensity value. ThisR intensity, obtained from two delineated fat regions (purple). (II) MRI delineated
MR intensities were binned. (V) Textural MR-IBMs were extracted from matrices
L.V. van Dijk et al. / Radiotherapy and Oncology 128 (2018) 459–466 461approach is a simplified tissue-based MRI Intensity standardisation
[21]; to our knowledge, no MRI standardisation approaches are
known for the head and neck area or radiomics purposes.Candidate MRI-IBMs, dose and clinical parameters
Parotid glands were delineated for clinical planning purposes
on the planning CT, according to guidelines of Brouwer et al.
[22]. Dosimetric parameters were extracted from these volumes.
MR images were rigidly matched to the CT scans, and the CT
contours were transferred to the MR images. The MRI parotid
delineations were manually corrected where necessary in both
datasets.
MRI characteristics of the delineated parotid glands were quan-
tified in intensity and texture MR-image biomarkers (MR-IBMs).
Intensity MR-IBMs represent first-order MR-intensity characteris-
tics, such as the mean, minimum, maximum, standard deviation
and root mean square of the MR-intensity values.
Furthermore, the MR-intensity heterogeneity was quantified by
the textural MR-IBMs. These were extracted from the grey level co-
occurrence matrix (GLCM) [23] and grey level run-length matrix
(GLRLM) [24,25], where GLCM describes the grey level transitions,
GLRLM describes the directional grey level repetitions. The texture
IBMs were evaluated in 2D only, which means that the average of
MR-IBM values from GLCM and GLRLM of 4 independent directions
in-plain were used. Intensity values were discretized from 0 to 450
with a bin size of 25 standardised MR-units [26].
For the complete list of the 21 intensity and 43 textural MR-
IBMs (25 GLCM and 18 GLRLM) see Supplementary data 2. The
extraction process (Fig. 1) was performed in MATLAB 2014a and
all definitions and formulas were according to the ‘Image biomar-
ker standardisation initiative’ [27].Multivariable analysis and model performance
Reference model
A multivariable logistic regression reference model based on
the mean dose to the both parotid glands and patient-reported
xerostomia at the start of radiotherapy (Xerbaseline) was fitted in
the training cohort [3,4]. Xerbaseline was dichotomized as none vs.
any in the UMCG dataset and larger than 1 in the MSKCC dataset.
Intensity and textural MR-IBMs selection
To understand the contribution of the different types of
MR-IBMs to the reference model, intensity and textural based
MR-IBM models were considered separately. Model training was
performed in the UMCG cohort only. MR-IBM values were
normalized by subtracting each value by the average IBM value
and then dividing by standard deviation of that IBM variable.
A pre-selection based on (Pearson) correlation was performed
to reduce the effects of overfitting and multicollinearity. If the cor-
relation between two candidate MR-IBMs was larger than 0.80,
only the variable with the highest association with Xer12m was
selected.
Multivariable logistic analysis of the pre-selected MR-IBMs was
performed together with the mean parotid dose and Xerbaseline.
Based on largest significant log-likelihood differences, step-wise
forward selection was used to select MR-IBM predictors [28]
(p-value <0.01).
The internal validity of the variable selection was estimated by
repeating the entire variable selection procedure (variable normal-
ization, pre-selection and forward selection) 1000 times with a
bootstrap procedure with replacement (i.e. with repetition and
same sample size). The most frequently selected variables were
considered the final model. Model optimism was estimated by cal-
culating the average difference between the performance of themodels in each bootstrap and in the original sample, as suggested
by the TRIPOD statement [29].
Trained on the UMCG cohort, the MR-IBM models were exter-
nally validated in the MSKCC cohort. The model performance mea-
sures were the area under the ROC (receiver operating
characteristic) curve (AUC), Nagelkerke’s R2 and the discrimination
slope. Model calibration was tested with the average slope and
intercept of the models trained on the bootstrap samples that were
tested on the original data. The coefficients were corrected for opti-
mism accordingly. In addition, the model improvement was deter-
mined with the Likelihood-ratio test, Integrated Discrimination
Improvement (IDI) and DeLong’s test (testing if AUC significantly
improves). The R-package Regression Modelling Strategies (version
4.3-1) [30] and pROC (version 1.8) were used for these purposes.Inter-variable relationships
The relation between predictive IBMs and Xerbaseline were inves-
tigated with the Pearson correlation and univariable logistic anal-
ysis, respectively.Results
Patient characteristics are depicted in Table 1. Generally, all
patients received bilateral irradiation. The majority of the patients
had oropharyngeal carcinomas and did not report any Xerbaseline
(59% in the UMCG cohort; 56% in the MSKCC cohort). Moderate-
to-severe xerostomia 12 months after radiotherapy (Xer12m) was
reported by 34 (50%) of the 68 patients in the UMCG cohort and
by 10 (40%) of 25 patients from the MSKCC cohort. In addition,
the average (±standard deviation) mean PG dose was 31.8 ± 10.9
Gy and 22.0 ± 8.8 Gy in the UMCG and MSKCC cohort, respectively.
Mean dose to both parotid glands performed slightly better than
the contra-lateral gland in this cohort, probably due to the tumour
location (oropharynx) and advance N-stage, resulting in compara-
ble contra- and ipsi-lateral doses.
The reference model based on mean PG dose and Xerbaseline was
fitted to the training dataset. The model characteristics and the
performance measures (AUC = 0.81 (95%CI:0.71–0.91), R2 = 0.39)
are depicted in Tables 2 and 3. The reference model showed
reduced performance in the external dataset (AUCexternal.val. = 0.65
(0.41–0.88), R2external.val. = 0.07).
Resulting from the bootstrapped variable selection of the inten-
sity MR-IBMs, the 90th intensity percentile (P90) of standardised
MRI-units to fat tissue was most frequently selected (175 times
of 1000 bootstrapped samples; see Supplementary data 3 for fre-
quency plots). This MR-IBM had both a univariable (OR = 1.03
(1.01–1.05); p = 0.004) and multivariable (Table 2) association
with Xer12m. The positive regression coefficient reveals that high
P90 is associated with higher risk of developing Xer12m (Table 2).
Fig. 2 depicts example patients with high and low P90 values.
The P90 added significantly to the variables of the reference
model (Likelihood-ratio test; p = 0.002; IDI; p = 0.004), and
resulted in a substantial and significant improvement of the
model performance measures (DeLong’s test; p = 0.04), increasing
the reference model’s AUC of 0.81 (95%CI:0.71–0.91; R2 = 0.39,
AUCinternal.val. = 0.78) to 0.88 (0.79–0.96; R2 = 0.51, AUCinternal.val. =
0.84) for the intensity MR-IBM model (Table 3). The NTCP-curves
for different P90 values are depicted in Fig. 3.
The performance of the P90 model remained good when
externally validated in the MSKCC dataset (AUCexternal.val. = 0.83
(0.66–0.99), R2external.val. = 0.36). In addition, univariable analysis in
the external dataset showed a significant association of P90 with
Xer12m (p = 0.039).
From the texture MR-IBMs, the Grey Level Non-uniformity Nor-




Characteristics N = 68 % N = 25 %
Sex
Female 27 40 5 20
Male 41 60 20 80
Age
18–65 years 47 69 23 92
>65 years 21 31 2 8
Tumour site
Oropharynx 42 62 17 68
Nasopharynx 5 7 7 28
Hypopharynx 6 9 – –
Larynx 10 15 – –
Oral cavity 2 3 – –
Other 3 4 1 4
Tumour classification
Tx 2 8
T1 11 16 8 32
T2 20 29 8 32
T3 16 24 4 16
T4 21 31 3 12
Node classification
N0 19 28 7 28
N1 6 9 4 16
N2 42 62 14 56
N3 1 1 – –
Systemic treatment
Yes 42 62 22 88
No 22 32 3 12
Cetuximab 4 6 – –
Treatment technique
IMRT 60 88 15 60
VMAT 8 12 10 40
Neck irradiation
Bilateral 62 91 20 80
Unilateral 1 1 4 16
No 5 7 1 4
Baseline Xerostomia
No 40 59 14 56
Any 28 41 11 44
Abbreviations: IMRT: Intensity-Modulated Radiation Therapy; VMAT: Volumetric
Arc Therapy; UMCG: University Medical Center Groningen; MSKCC: Memorial





































































































































































































































































































































































































































































































































462 MR-IBMs improve xerostomia predictionsamples; see Supplementary data 3). Derived from the GLRLM, this
texture MR-IBM is high when high concentrations of runs with the
same grey level are present in the volume of interest (for formula
see Supplementary data 2). This texture MR-IBM had both a nega-
tively significant univariable (OR = 0.34, 95%CI 0.20–0.74;
p = 0.004) and multivariable (Table 2) association with Xer12m,
indicating that low GLNnor values were related with a higher risk
of xerostomia.
When adding GLNnor to the reference model, model perfor-
mance significantly improved (Likelihood-ratio test; p = 0.002;
IDI; p < 0.001). The performance of the resulting texture MR-IBM
model (Table 2) was good (AUC: 0.88 (0.79–0.96), R2 = 0.52;
AUCinternal.val. = 0.84) and significantly improved compared to the
reference model (DeLong’s test; p = 0.03). The NTCP curves are
depicted in Fig. 3.
On external validation, the texture MR-IBM model performed
well (AUCexternal.val. = 0.83(0.67–0.99), R2external.val. = 0.31). Univari-
able analysis also showed a significant association of GLNnor with
Xer12m (p = 0.036).
The internal validation calibration slope and intercept showed
reasonable goodness-of-fit for both the intensity and texture mod-


























































































































































































































































































































































































































































































































































































































































































































































































L.V. van Dijk et al. / Radiotherapy and Oncology 128 (2018) 459–466 463dataset (MSKCC + UMCG), and showed similar coefficients and per-
formance measures (Supplementary data 4).
The intensity and texture MR-IBM P90 and GLNnor were highly
correlated (r = 0.85 (95%CI: 0.90–0.78); p < 0.001). In a multi-
variable analysis, the addition of GLNnor did not add significant
information in predicting Xer12m with P90 and vice versa
(Likelihood-ratio test; p > 0.27). Furthermore, univariable logistic
analysis showed no significant association between Xerbaseline and
P90 (p = 0.45) or GLNnor (p = 0.29).Discussion
In previous studies we showed that more heterogeneous CT
intensity characteristics and low metabolic 18FDG-PET activity of
the parotid glands were related to a higher risk of xerostomia 12
months after radiotherapy (Xer12m) [14,15]. These findings led to
thehypothesis that the fat-to-functional parenchymal parotid tissue
ratio is an important pre-treatmentmarker to improve prediction of
Xer12m. The results of the current study also support this hypothesis.
Other recent studies also showed that pre-treatment informa-
tion extracted from CT images, quantifying the parotid gland tex-
ture [31] and shape [32], were associated with observed
radiation-induced xerostomia. Additionally, several studies have
shown associations between xerostomia and parotid gland
changes in CT data [33,34]. The current study is novel by investi-
gating pre-treatment MR intensities of the parotid glands, provid-
ing high contrast soft-tissue information, in relation to late patient-
rated xerostomia.
MRI characteristics of the parotid glands, quantified in pre-
treatment MR-IBMs, were significantly associated to Xer12m. More-
over, the Xer12m prediction improved with the addition of MR-
IBMs to the reference model using mean parotid glands dose and
baseline complaints only (from an AUC of 0.81 to 0.88). These
results were also valid in an independent external cohort, where
the performance of the reference model (AUCexternal.val. = 0.65)
was low compared to the MR-IBM models (AUCexternal.val. = 0.83).
This underlines the importance of tissue-specific characteristics
in predicting and understanding the development of radiation-
induced toxicities, which is becoming increasingly important in
the selection of patients for more advanced radiation techniques
[6,7] and to tailor the treatment to the patient specifically [5].
The most frequently selected intensity MR-IBM was the P90,
indicating the 90th percentile of the MR-intensities of the parotid
glands. Since the MR-intensity values were standardised to fat,
fat tissue can be assumed to have comparable MR-intensity
between patients. Since fat has a short T1 relaxation time com-
pared to parenchymal or muscle tissue, it is presented with a high
signal intensity in T1-weighted images [35]. Hence high P90 values
relate to high fat concentration in the parotid gland. More specifi-
cally, if at least 10% of the volume of the parotid gland has high
intensity values, patients were at higher risk of developing late
xerostomia. However, this volume percentage should be evaluated
with caution, since using the simpler ‘mean standardized T1 inten-
sity’ also significantly improved the reference model (AUC = 0.86;
Likelihood-ratio test: p = 0.005). Moreover, 16 of the 21 intensity
MR-IBMs and 34 of the 43 texture MR-IBMs also contributed sig-
nificantly, as single variables, to the reference model in predicting
Xer12m (Supplementary data 5). This indicates that other MR-IBMs
that are also related to parotid gland intensity and texture, can give
similar results as P90 and GLNnor.
The values of the selected texture MR-IBM, GLNnor are low if
grey values are equally distributed over all grey levels, i.e. more
heterogeneity. Lower GLNnor values were associated with a higher
risk of developing xerostomia. This was also demonstrated in a
previous study based on CT parotid gland IBMs [14]. Noteworthy,
Fig. 2. Examples of patients with low (A–C) and high (D–F) P90 values of the parotid glands. Accordingly, the patients in the bottom row are more at risk of developing late
xerostomia than those in the top row.
Fig. 3. Normal Tissue Complication Probability (NTCP) models for Xer12m based on the MR-IBM P90 (left) and GLNnor (right) (Table 2). Plotted against the mean dose of both
parotid gland, NTCP curves are given for the mean (in green) plus/minus one (turquois/yellow) and two (blue/orange) standard deviations of the P90 (m = 234.89, r = 31.80)
and GLNnor (m = 0.18, r = 0.03) values for Xerbaseline = 0.
464 MR-IBMs improve xerostomia predictionthe reverse of GLNnor is ‘entropy’, which was the second most fre-
quently selected intensity MR-IBM (Supplementary data 3). More-
over, GLNnor was highly correlated with P90, which suggests that
parotid glands with high (fat related) MR signal intensities weremore heterogeneous. More research in larger datasets is necessary
to determine whether both characteristics are relevant in the
development of xerostomia and the generalisability of P90 and
GLNnor, or whether they reflect similar biological information.
L.V. van Dijk et al. / Radiotherapy and Oncology 128 (2018) 459–466 465The theoretical and qualitative evaluation of the predictive MR-
IBMs suggested a relation with the fat concentration and hetero-
geneity of the parotid gland. In previous work, unrelated to the
oncology field, Izumi et al. [36] presented an MRI-based grading
of the severity of parotid impairment for patients with Sjögren’s
syndrome that was based on similar image characteristics: high
T1-weigted signal intensity areas (e.g. fat tissue) and heterogeneity
in the parotid glands. Another study by Izumi et al. [37] also
showed a relationship between increased signal intensities on
T1-weighted MR images and impaired parotid function for patients
suffering from hyperlipidaemia. The findings of the current and
studies suggest that increased fat concentration in the parotid
gland, which may be caused by parenchymal changes due to lipid
infiltration, can increase the probability of developing xerostomia
after radiotherapy.
MRI offers the advantage of non-invasively acquired images
with high soft tissue contrast without the use of radiation with
respect to CT and PET imaging. However, it is a complex image
modality due to the large range of possible acquisition settings,
and requires intensity standardisation. This study and previous
studies have both indicated that PET and MR IBMs seem to perform
better than the CT IBMs in identifying patients that develop xeros-
tomia [14,15]. Studies including IBMs from all three image modal-
ities are necessary to determine which modality is most optimal in
this context, or whether they can add to each other in predicting
late xerostomia. The analyses of the current study were based on
relatively simple T1-weigthed TSE, which is widely used and
requires no administration of intravenous contrast agents. How-
ever, more sophisticated MRI sequences may better differentiate
between fat and functional parotid tissue (i.e. combinations of
non- and fat saturated images or functional information (e.g.
DIXON, Diffusion Weighted or Dynamic contrast-enhanced imag-
ing)). In addition, IBMs extracted fromwavelet transformed images
might improve the performance of the models presented in the
current study.
Limitations of the present study are the small cohort sizes and
the large variability in MR acquisition parameters in the MSKCC
cohort compared to the training cohort. Firstly, the resolution
had a relative large range in these scans. This can impact the tex-
ture IBMs, which depend on the spatial intensity distribution
[38,39]. Secondly, patients in the MSKCC cohort were scanned
without a thermoplastic mask, resulting in parotid glands defor-
mation due to the music headphones that patients wore during
acquisition. Finally, MSKCC scans were acquired with different
field strengths, and scanners from different vendors. Even though
part of this variability should be captured by MRI standardisation,
this can influence the MRI intensity and contrast. An additional
limitation is the lack of one-to-one correspondence in xerostomia
assessments between the two cohorts. However, a careful match-
ing was performed such that the two moderate-to-severe assess-
ments would be as similar as possible. Despite these limitations,
the performance of the MR-IBM models was good when tested in
the MSKCC dataset, suggesting that these IBMs were robust to vari-
ability in image acquisition parameters. The simplicity of the P90
metric likely contributed to successful validation.
Driven by the hypothesis, the MRI intensity standardisation was
linearly performed to ensure similar fat tissue intensities between
patients. However, this is in reality not a linear problem [40]. Our
approach is simple, and could be regarded as a starting point to
improve the standardisation so that not only subcutaneous fat is
generalised between patients, but also other tissues, such as mus-
cle. Additionally, mainly due to the presence of field inhomogene-
ity’s, scans can have intensity variations within the scan, for which
sophisticated bias field correction algorithms have been developed
for brain MR images [41]. The above described corrections were
explored for this dataset, however, the effect of these correctionson IBM analysis is currently unknown, and needs further
investigation.
In conclusion, the results of the current study support the
hypothesis that a high fat concentration, quantified in MR-IBMs,
within the parotid glands is related to a higher risk of developing
xerostomia 12 months after radiotherapy (Xer12m). The prediction
performance of Xer12m based on parotid dose and baseline xerosto-
mia only was improved by the addition of the predictive intensity
MR-IBM P90. These results were maintained in a small external
validation cohort. MR-IBMs appear to be good candidates to pre-
dict the patient-specific response of healthy tissue to radiation
dose. However, more research in larger patient cohorts is needed
to further validate our conclusions.Conflict of interest
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